Saluda Medical (ASX:SLD) said the first procedures in the US using the Evoke CAP24 surgical paddle lead were performed on Friday, July 10, and Tuesday, July 14, according to a Thursday Australian bourse filing.
Its Evoke system is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy.
Its shares jumped 3% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments